Recurrent retroperitoneal sarcomas: Clinical outcomes of surgical treatment and prognostic factors.


Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356

Informations de publication

Date de publication:
05 2021
Historique:
received: 25 05 2020
revised: 24 08 2020
accepted: 31 08 2020
pubmed: 21 9 2020
medline: 12 10 2021
entrez: 20 9 2020
Statut: ppublish

Résumé

Locoregional recurrence after resection of primary retroperitoneal sarcoma (RPS) is a challenging therapeutic issue. The objective of this study was to identify clinicopathological factors predictive of overall survival (OS) and disease specific survival (DSS) after reoperation for recurrent RPS. We retrospectively collected data from the medical records of 800 patients who underwent resection for sarcoma at our Institution, from 1983 to 2015. Among these patients, 120 were treated for retroperitoneal sarcoma and 55 had a locoregional recurrence (LR). Four of them did not undergo surgery and thus were excluded from this study leaving 51 cases available for data analysis. Univariate and multivariate survival analyses were performed to identify prognostic factors. Median overall survival was 33 months. The 1-year, 3-year and 5-year OS rates were 75.5%, 47.1% and 31.6% respectively. Multivariate Cox regression analysis suggested that extension of surgery (P = 0.026), surgical margin status (P = 0.015) and histological grade of recurrent tumor (P = 0.047) were independent prognostic factors for OS. Median DSS was 48 months. The 1-year, 3-year and 5-year DSS rates were 79.2%, 53.1% and 40.9%, respectively. At multivariate analysis, predictors of DSS were extension of surgery (P = 0.004), margin status (P = 0.011), histological grade of recurrent tumor (P = 0.008), and disease free interval (DFI) (P = 0.020). As regards histological subtype of recurrent RPS, at univariate analysis, well-differentiated liposarcoma (WDLS) was associated with better OS and DSS (P = 0.052 and P = 0.016 respectively) compared to dedifferentiated liposarcoma (DDLS). According to our findings, surgery is more beneficial in patients with low-grade sarcoma, WDLS and long DFI. The achievement of clear resection margins, rather than performing a multivisceral resection, appears to be a key factor to improve OS and DSS.

Sections du résumé

BACKGROUND AND PURPOSE
Locoregional recurrence after resection of primary retroperitoneal sarcoma (RPS) is a challenging therapeutic issue. The objective of this study was to identify clinicopathological factors predictive of overall survival (OS) and disease specific survival (DSS) after reoperation for recurrent RPS.
PATIENTS AND METHODS
We retrospectively collected data from the medical records of 800 patients who underwent resection for sarcoma at our Institution, from 1983 to 2015. Among these patients, 120 were treated for retroperitoneal sarcoma and 55 had a locoregional recurrence (LR). Four of them did not undergo surgery and thus were excluded from this study leaving 51 cases available for data analysis. Univariate and multivariate survival analyses were performed to identify prognostic factors.
RESULTS
Median overall survival was 33 months. The 1-year, 3-year and 5-year OS rates were 75.5%, 47.1% and 31.6% respectively. Multivariate Cox regression analysis suggested that extension of surgery (P = 0.026), surgical margin status (P = 0.015) and histological grade of recurrent tumor (P = 0.047) were independent prognostic factors for OS. Median DSS was 48 months. The 1-year, 3-year and 5-year DSS rates were 79.2%, 53.1% and 40.9%, respectively. At multivariate analysis, predictors of DSS were extension of surgery (P = 0.004), margin status (P = 0.011), histological grade of recurrent tumor (P = 0.008), and disease free interval (DFI) (P = 0.020). As regards histological subtype of recurrent RPS, at univariate analysis, well-differentiated liposarcoma (WDLS) was associated with better OS and DSS (P = 0.052 and P = 0.016 respectively) compared to dedifferentiated liposarcoma (DDLS).
CONCLUSIONS
According to our findings, surgery is more beneficial in patients with low-grade sarcoma, WDLS and long DFI. The achievement of clear resection margins, rather than performing a multivisceral resection, appears to be a key factor to improve OS and DSS.

Identifiants

pubmed: 32950313
pii: S0748-7983(20)30722-8
doi: 10.1016/j.ejso.2020.08.030
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1201-1206

Informations de copyright

Copyright © 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Auteurs

Saveria Tropea (S)

Surgical Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Padova, Italy. Electronic address: saveria.tropea@iov.veneto.it.

Simone Mocellin (S)

Surgical Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Padova, Italy; Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padua, Padova, Italy. Electronic address: simone.mocellin@iov.veneto.it.

Giovanni Battista Damiani (GB)

Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padua, Padova, Italy. Electronic address: damianigv@libero.it.

Roberto Stramare (R)

Radiology Unit, University of Padua, Padova, Italy.

Camillo Aliberti (C)

Diagnostic Imaging Department, Pederzoli Hospital, Peschiera del Garda, Italy. Electronic address: caliberti@ospedalepederzoli.it.

Paolo Del Fiore (P)

Surgical Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Padova, Italy. Electronic address: paolo.delfiore@iov.veneto.it.

Carlo Riccardo Rossi (CR)

Surgical Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Padova, Italy; Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padua, Padova, Italy. Electronic address: carlor.rossi@unipd.it.

Marco Rastrelli (M)

Surgical Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Padova, Italy. Electronic address: marco.rastrelli@iov.veneto.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH